Search

From the Podium to Your Practice: Dr. Jonathan Silverberg Reviews New Data Showing That Upadacitinib Beat Dupilumab Across All Ranked Secondary End Points in Head-to-head AD Trial

Jonathan Silverberg, MD, PhD, MPH, Director of Clinical Research at The George Washington University School of Medicine and Health Sciences in Washington, DC, breaks down the new data from LEVEL-UP, a head-to-head study evaluating upadacitinib (Rinvoq, AbbVie) vs. dupilumab (Dupixent, Sanofi & Regeneron) for the treatment of adolescents and adults with moderate to severe atopic dermatitis who had inadequate response to systemic therapy or when systemic therapies were not advised.  The late-breaking data, presented at the 2024 Revolutionizing Alopecia Areata, Vitiligo, and Eczema Conference in Chicago, Illinois, showed that upadacitinib bested dupilumab for all ranked secondary end points of LEVEL-UP, including complete skin clearance and rapid resolution of itching in patients with severe itch.